EirGen Pharma Product Eir-118 Passes Bioequivalence Study in EU

EirGen Pharma are pleased to announce that EIR-118, a product which was developed as a treatment for cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS), has successfully passed its Bioequivalence Study in the EU.